Newron Pharmaceuticals S.p.A. (SWX:NWRN)
Switzerland · Delayed Price · Currency is CHF 11.66
-0.14 (-1.19%)
Jul 31, 2026, 5:30 PM CET
Newron Pharmaceuticals Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 12.19 | 6.93 | 6.34 | 13.42 | 25.02 |
Short-Term Investments | 16.69 | 2.89 | 6.26 | 9.35 | 9.58 |
Cash & Short-Term Investments | 28.88 | 9.83 | 12.6 | 22.77 | 34.59 |
Cash Growth | 193.87% | -22.01% | -44.68% | -34.17% | 10.70% |
Accounts Receivable | 2.54 | 42.12 | 2.02 | 1.94 | 1.31 |
Other Receivables | 3.62 | 4.94 | 3.16 | 3.03 | 2.74 |
Receivables | 6.16 | 47.06 | 5.18 | 4.97 | 4.05 |
Prepaid Expenses | 3.04 | 4.22 | 1.87 | 0.75 | 0.78 |
Total Current Assets | 38.08 | 61.1 | 19.65 | 28.49 | 39.43 |
Property, Plant & Equipment | 0.74 | 0.83 | 0.41 | 0.53 | 0.58 |
Other Intangible Assets | 0 | - | - | - | 0 |
Other Long-Term Assets | 1.24 | 1.97 | 5.81 | 8.18 | 10.48 |
Total Assets | 40.06 | 63.91 | 25.87 | 37.2 | 50.49 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 2.32 | 2.47 | 2.02 | 1.91 | 1.5 |
Accrued Expenses | 3.4 | 4.94 | 3.49 | 2.17 | 1.1 |
Current Portion of Long-Term Debt | 37.46 | 13.41 | 22.28 | - | - |
Current Portion of Leases | 0.12 | 0.14 | 0.18 | 0.17 | 0.15 |
Other Current Liabilities | 6.83 | 2.55 | 0.97 | 0.79 | 0.9 |
Total Current Liabilities | 50.13 | 23.51 | 28.93 | 5.04 | 3.65 |
Long-Term Debt | - | 36.24 | 25.75 | 45.17 | 42.54 |
Long-Term Leases | 0.58 | 0.67 | 0.21 | 0.33 | 0.39 |
Pension & Post-Retirement Benefits | 0.48 | 0.46 | 0.41 | 0.47 | 0.58 |
Other Long-Term Liabilities | - | 1.57 | 0.47 | 0.22 | 0.21 |
Total Liabilities | 51.19 | 62.45 | 55.77 | 51.23 | 47.38 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 4 | 3.99 | 3.57 | 3.57 | 3.57 |
Additional Paid-In Capital | - | - | - | - | 5.1 |
Retained Earnings | -18.27 | 10.69 | -21.4 | -22.81 | -20.12 |
Comprehensive Income & Other | 3.13 | -13.22 | -12.08 | 5.21 | 14.55 |
Shareholders' Equity | -11.14 | 1.46 | -29.91 | -14.03 | 3.11 |
Total Liabilities & Equity | 40.06 | 63.91 | 25.87 | 37.2 | 50.49 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 38.16 | 50.47 | 48.42 | 45.66 | 43.08 |
Net Cash (Debt) | -9.29 | -40.64 | -35.82 | -22.89 | -8.49 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -0.47 | -1.98 | -2.01 | -1.28 | -0.48 |
Filing Date Shares Outstanding | 20.01 | 19.96 | 17.85 | 17.85 | 17.85 |
Total Common Shares Outstanding | 20.01 | 19.96 | 17.85 | 17.85 | 17.85 |
Working Capital | -12.05 | 37.6 | -9.27 | 23.45 | 35.77 |
Book Value Per Share | -0.56 | 0.07 | -1.68 | -0.79 | 0.17 |
Tangible Book Value | -11.14 | 1.46 | -29.91 | -14.03 | 3.11 |
Tangible Book Value Per Share | -0.56 | 0.07 | -1.68 | -0.79 | 0.17 |